EGFR and neoplasm: Interactions between inflammatory cell populations and tumor molecular drivers, such as EGFR, KRAS, ALK, or TP53 mutations, can shape the tumor microenvironment, alter cytokine signaling, and modulate the degree of immune activation or suppression [12].